Dr. TARUN WADHWA

Dr. Dr. TARUN WADHWA

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2022 in Cureus
Verified
Journal Article
Open access
SCSumant Chavda
Sumant Chavda
SRSyed Arman Rabbani
Syed Arman Rabbani
DWDr. TARUN WADHWA
Dr. TARUN WADHWA
Osteoarthritis (OA) is a degenerative joint disease that causes persistent joint pain and stiffness of mainly the large peripheral weight-bearing joints. It is a leading cause of functional disability and poor quality of life. Various modalities of therapy are recommended by different research organizations at different stages of OA including non-pharmacological, pharmacological, and surgical interventions. Intra-articular injections of hyaluronic acid (HA) is widely used for over three decades in the treatment of OA. However controversies exist regarding its safety and efficacy, the number of injections and courses, type of preparation, duration of its effects, and combining it with other drugs or molecules. This study aimed to review the most recent data available in the published literature to address these. Electronic databases like Medline, Embase, ProQuest, and Google Scholar were searched for articles using keywords, intraarticular injections, hyaluronic acid, and osteoarthritis knee. The review was carried out as per PRISMA guidelines. Thirty-eight randomized control trials (RCTs) investigating the efficacy and safety of intra-articular injection of HA were included in the systematic review. Out of the 38 studies, 22 (57.9%) were double-blind, eight (21%) single-blind, three (7.9%) non-blind, four (10%) with simple randomization, and one (2.7%) was open-labeled. Total 5,025 patients were included in these studies. The mean age of the patients was 60.28 years and the osteoarthritis grade of the knee joint was 1 to 3. HA was studied as a test preparation in 19 (50%) while in another 19 (50%) it was studied as a control. In 24 (63.2%) studies, HA was used as high molecular weight preparation in eight (21%) as low molecular weight preparation while in six studies the information was not available. HA was used as a standalone preparation in 31 studies, in two studies it was injected with platelet-rich plasma (PRP) and with either low-level laser therapy (LLLT), triamcinolone (TA), betamethasone (CS), poly deoxyribonucleotide (PDRN) or dexamethasone (DX) in one study each. In the majority of the studies, HA was given as a single injection (52.6% studies) or weekly three injections (28.9% studies). In 13.2 %, it was given as weekly 5 injections and in 5.3% as weekly two injections. IA-HA injections have a limited role in the treatment of knee osteoarthritis in those patients who do not have sufficient pain relief with topical or oral medication and physical therapy. It is safe and effective except for minor side effects such as local pain and swelling lasting for a few days. Severe allergic reactions are extremely rare. They provide adequate pain relief and functional improvement for up to six months irrespective of a number of injections and type of preparations used. The combination formulations with corticosteroids or PRP or MSCs show better results than HA alone. Combining HA with newer molecules such as peptides or diclofenac for sustained and disease-modifying effects requires more studies in the future.

10 May 2025 in New Microbes and New Infections
Verified
Journal Article
Open access
Shriyansh SrivastavaShriyansh Srivastava
Shriyansh Srivastava
Ranjit SahRanjit Sah
Ranjit Sah
MBMALAKAPOGU RAVINDRA BABU
MALAKAPOGU RAVINDRA BABU
DSDeepika Sharma
Deepika Sharma
Dheeraj SharmaDheeraj Sharma
Dheeraj Sharma
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
Oropouche fever, caused by the Oropouche virus (OROV), has become a significant public health concern. Recent outbreaks highlight its increasing global spread, driven by environmental, social, and ecological factors. The disease presents clinical similarities to other arboviral infections, making accurate diagnosis essential for effective management and prevention. This article examines the epidemiological patterns of Oropouche fever, including its geographic distribution and outbreak drivers. It explores the clinical manifestations of the disease, focusing on common symptoms, complications such as fatal cases and fetal abnormalities, and the necessity of differential diagnosis. The pathophysiology of OROV infection is analyzed, detailing viral entry mechanisms, immune responses, and the role of vectors in transmission. Additionally, we assess diagnostic challenges, comparing serological and molecular methods while identifying their limitations. Therapeutic strategies are also reviewed, including symptomatic treatments and potential antiviral candidates. Findings indicate that OROV infections mimic other arboviral diseases, complicating clinical diagnosis. Current diagnostic tools have limitations in accuracy and accessibility, particularly in resource-limited settings. Symptomatic treatment remains the primary approach, as no specific antiviral therapies or vaccines exist. The study identifies gaps in diagnostic development, vaccine research, and public health surveillance. Oropouche fever threatens global health, necessitating improved surveillance, diagnostic tools, and targeted research efforts. Enhancing epidemiological studies and developing effective vaccines will mitigate its impact. Strengthening public health strategies can help control the spread of OROV and reduce its burden on affected populations.

18 March 2025 in Infectious Medicine
Verified
Journal Article
Open access
SPSejal Porwal
Sejal Porwal
RMRishabh Malviya
Rishabh Malviya
SSSathvik Belagodu Sridhar
Sathvik Belagodu Sridhar
JSJAVEDH SHAREEF
JAVEDH SHAREEF
DWDr. TARUN WADHWA
Dr. TARUN WADHWA
• Fever, headache, myalgia, and photophobia are common; severe cases include meningitis and encephalitis. • OROV can pass from mother to fetus, causing issues like microcephaly and stillbirths. • Up to 70% of patients report recurring symptoms like headache and fatigue after initial recovery. • Live attenuated vaccine candidate demonstrated safety and immunity in clinical trials. • Real-time RT-PCR detects OROV with 93% efficacy during the acute phase within five days of symptom onset. • Two deaths were reported in Bahia, Brazil, in 2024, marking the first confirmed OROV-related fatalities.

25 June 2025 in Journal of Clinical Orthopaedics and Trauma
Verified
Journal Article
Closed access
BPBhumika Parashar
Bhumika Parashar
RMRishabh Malviya
Rishabh Malviya
SSSathvik Belagodu Sridhar
Sathvik Belagodu Sridhar
DWDr. TARUN WADHWA
Dr. TARUN WADHWA
JSJavedh Shareef
Javedh Shareef

18 January 2025 in Infectious Medicine
Verified
Journal Article
Open access
BPBhumika Parashar
Bhumika Parashar
RMRishabh Malviya
Rishabh Malviya
SSSathvik Belagodu Sridhar
Sathvik Belagodu Sridhar
DWDr. TARUN WADHWA
Dr. TARUN WADHWA
STSirajunisa Talath
Sirajunisa Talath
JSJavedh Shareef
Javedh Shareef
• Eastern equine encephalitis (EEE) virus spread by mosquito. • Nearly 90 % of patients suffering from EEE virus lasting neurological sequelae, while the death rate for EEEV infections may reach 75 %. • Severity of disease is also affected by environmental and climatic changes. • The initial targets of virus infection are dendritic cells and fibroblasts, which cause the activation of self-defense systems. • Patients may experience a loss of consciousness or coma, which ultimately leads to death.

8 July 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
SPSejal Porwal
Sejal Porwal
RMRishabh Malviya
Rishabh Malviya
MWMusarrat Warsi
Musarrat Warsi
Ameeduzzafar zafarAmeeduzzafar zafar
Ameeduzzafar zafar
MKMohammad Khalid
Mohammad Khalid
DWDr. TARUN WADHWA
Dr. TARUN WADHWA